1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
2
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Estimating the world cancer burden: Globocan 2000. Int J Cancer.
94:153–156. 2001. View
Article : Google Scholar : PubMed/NCBI
|
3
|
Colomiere M, Ward AC, Riley C, et al:
Cross talk of signals between EGFR and IL-6R through JAK2/STAT3
mediate epithelial-mesenchymal transition in ovarian carcinomas. Br
J Cancer. 100:134–144. 2009. View Article : Google Scholar :
|
4
|
Ono K, Tanaka T, Tsunoda T, et al:
Identification by cDNA microarray of genes involved in ovarian
carcinogenesis. Cancer Res. 60:5007–5011. 2000.PubMed/NCBI
|
5
|
Rhoades MW, Reinhart BJ, Lim LP, Burge CB,
Bartel B and Bartel DP: Prediction of plant microRNA targets. Cell.
110:513–520. 2002. View Article : Google Scholar : PubMed/NCBI
|
6
|
Lu Y, Zhou Y, Qu W, Deng M and Zhang C: A
Lasso regression model for the construction of microRNA-target
regulatory networks. Bioinformatics. 27:2406–2413. 2011. View Article : Google Scholar : PubMed/NCBI
|
7
|
Ying SY, Chang DC and Lin SL: The microRNA
(miRNA): Overview of the RNA genes that modulate gene function. Mol
Biotech. 38:257–268. 2008. View Article : Google Scholar
|
8
|
Pritchard CC, Kroh E, Wood B, et al: Blood
cell origin of circulating microRNAs: a cautionary note for cancer
biomarker studies. Cancer Prev Res (Phila). 5:492–497. 2012.
View Article : Google Scholar
|
9
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20.
2013.PubMed/NCBI
|
10
|
Balch C, Naegeli K, Nam S, et al: A unique
histone deacetylase inhibitor alters microRNA expression and signal
transduction in chemoresistant ovarian cancer cells. Cancer Biol
Ther. 13:681–693. 2012. View Article : Google Scholar : PubMed/NCBI
|
11
|
Aydoğdu E, Katchy A, Tsouko E, et al:
MicroRNA-regulated gene networks during mammary cell
differentiation are associated with breast cancer. Carcinogenesis.
33:1502–1511. 2012. View Article : Google Scholar
|
12
|
Lu J, Getz G, Miska EA, et al: MicroRNA
expression profiles classify human cancers. Nature. 435:834–838.
2005. View Article : Google Scholar : PubMed/NCBI
|
13
|
Garzon R, Fabbri M, Cimmino A, Calin GA
and Croce CM: MicroRNA expression and function in cancer. Trends
Mol Med. 12:580–587. 2006. View Article : Google Scholar : PubMed/NCBI
|
14
|
Cho WC: MicroRNAs: potential biomarkers
for cancer diagnosis, prognosis and targets for therapy. Int J
Biochem Cell Biol. 42:1273–1281. 2010. View Article : Google Scholar
|
15
|
Wu SF, Qian WY, Zhang JW, et al: Network
motifs in the transcriptional regulation network of cervical
carcinoma cells respond to EGF. Arch Gynecol Obstet. 287:771–777.
2013. View Article : Google Scholar
|
16
|
Higareda-Almaraz JC, Enríquez-Gasca Mdel
R, Hernández-Ortiz M, Resendis-Antonio O and Encarnación-Guevara S:
Proteomic patterns of cervical cancer cell lines, a network
perspective. BMC Sys Biol. 5:962011. View Article : Google Scholar
|
17
|
Zhai Y, Kuick R, Nan B, et al: Gene
expression analysis of preinvasive and invasive cervical squamous
cell carcinomas identifies HOXC10 as a key mediator of invasion.
Cancer Res. 67:10163–10172. 2007. View Article : Google Scholar : PubMed/NCBI
|
18
|
Tusher VG, Tibshirani R and Chu G:
Significance analysis of microarrays applied to the ionizing
radiation response. Proc Natl Acad Sci USA. 98:5116–5121. 2001.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Larsson O, Wahlestedt C and Timmons JA:
Considerations when using the significance analysis of microarrays
(SAM) algorithm. BMC Bioinformatics. 6:1292005. View Article : Google Scholar : PubMed/NCBI
|
20
|
Dennis G Jr, Sherman BT, Hosack DA, et al:
DAVID: Database for annotation, visualization and integrated
discovery. Genome Biol. 4:P32003. View Article : Google Scholar
|
21
|
Benjamini Y and Hochberg Y: Controlling
the false discovery rate: A practical and powerful approach to
multiple testing. J R Stat Soc Series B Stat Methodol. 57:289–300.
1995.
|
22
|
Papadopoulos GL, Reczko M, Simossis VA,
Sethupathy P and Hatzigeorgiou AG: The database of experimentally
supported targets: a functional update of TarBase. Nucleic Acids
Res. 37:D155–D158. 2009. View Article : Google Scholar :
|
23
|
Shannon P, Markiel A, Ozier O, et al:
Cytoscape: a software environment for integrated models of
biomolecular interaction networks. Genome Res. 13:2498–2504. 2003.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Zhang S, Jin G, Zhang XS and Chen L:
Discovering functions and revealing mechanisms at molecular level
from biological networks. Proteomics. 7:2856–2869. 2007. View Article : Google Scholar : PubMed/NCBI
|
25
|
Freeman LC: Centrality in social networks
conceptual clarification. Soc Networks. 1:215–239. 1979. View Article : Google Scholar
|
26
|
Fearon ER and Vogelstein B: A genetic
model for colorectal tumorigenesis. Cell. 61:759–767. 1990.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Ryu B, Jones J, Hollingsworth MA, Hruban
RH and Kern SE: Invasion-specific genes in malignancy: serial
analysis of gene expression comparisons of primary and passaged
cancers. Cancer Res. 61:1833–1838. 2001.PubMed/NCBI
|
28
|
Kitahara O, Furukawa Y, Tanaka T, et al:
Alterations of gene expression during colorectal carcinogenesis
revealed by cDNA microarrays after laser-capture microdissection of
tumor tissues and normal epithelia. Cancer Res. 61:3544–3549.
2001.PubMed/NCBI
|
29
|
Reddy KB, Jin G, Karode MC, Harmony JA and
Howe PH: Transforming growth factor beta (TGF beta)-induced nuclear
localization of apolipoprotein J/clusterin in epithelial cells.
Biochemistry. 35:6157–6163. 1996. View Article : Google Scholar : PubMed/NCBI
|
30
|
Yang CR, Leskov K, Hosley-Eberlein K, et
al: Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein
that signals cell death. Proc Natl Acad Sci USA. 97:5907–5912.
2000. View Article : Google Scholar : PubMed/NCBI
|
31
|
O’Sullivan J, Whyte L, Drake J and
Tenniswood M: Alterations in the post-translational modification
and intracellular trafficking of clusterin in MCF-7 cells during
apoptosis. Cell Death Differ. 10:914–927. 2003. View Article : Google Scholar
|
32
|
Klokov D, Leskov K, Araki S, et al: Low
dose IR-induced IGF-1-sCLU expression: a p53-repressed expression
cascade that interferes with TGFbeta1 signaling to confer a
pro-survival bystander effect. Oncogene. 32:479–490. 2013.
View Article : Google Scholar
|
33
|
Choi I, Kim J, Park JY and Kang SW:
Cotransin induces accumulation of a cytotoxic clusterin variant
that cotranslationally rerouted to the cytosol. Exp Cell Res.
319:1073–1082. 2013. View Article : Google Scholar : PubMed/NCBI
|
34
|
Santin AD, Zhan F, Bignotti E, et al: Gene
expression profiles of primary HPV16- and HPV18-infected early
stage cervical cancers and normal cervical epithelium:
identification of novel candidate molecular markers for cervical
cancer diagnosis and therapy. Virology. 331:269–291. 2005.
View Article : Google Scholar : PubMed/NCBI
|
35
|
Ahn WS, Bae SM, Lee JM, et al: Searching
for pathogenic gene functions to cervical cancer. Gynecol Oncol.
93:41–48. 2004. View Article : Google Scholar : PubMed/NCBI
|
36
|
Harima Y, Ikeda K, Utsunomiya K, et al:
Identification of genes associated with progression and metastasis
of advanced cervical cancers after radiotherapy by cDNA microarray
analysis. Int J Radiat Oncol. 75:1232–1239. 2009. View Article : Google Scholar
|
37
|
Ishikawa A, Suga T, Shoji Y, et al:
Genetic Variants of NPAT-ATM and AURKA are associated with an early
adverse reaction in the gastrointestinal tract of patients with
cervical cancer treated with pelvic radiation therapy. Int J Radiat
Oncol. 81:1144–1152. 2011. View Article : Google Scholar
|
38
|
Chen JJ, Silver D, Cantor S, Livingston DM
and Scully R: BRCA1, BRCA2 and Rad51 operate in a common DNA damage
response pathway. Cancer Res. 59(Suppl 7): 1752–1756. 1999.
|
39
|
Narayan G, Arias-Pulido H, Nandula SV, et
al: Promoter hyper-methylation of FANCF disruption of Fanconi
Anemia-BRCA pathway in cervical cancer. Cancer Res. 64:2994–2997.
2004. View Article : Google Scholar : PubMed/NCBI
|
40
|
Lagos-Quintana M, Rauhut R, Meyer J,
Borkhardt A and Tuschl T: New microRNAs from mouse and human. RNA.
9:175–179. 2003. View Article : Google Scholar : PubMed/NCBI
|
41
|
Makeyev EV, Zhang J, Carrasco MA and
Maniatis T: The MicroRNA miR-124 promotes neuronal differentiation
by triggering brain-specific alternative pre-mRNA splicing. Mol
Cell. 27:435–448. 2007. View Article : Google Scholar : PubMed/NCBI
|
42
|
Smirnova L, Gräfe A, Seiler A, Schumacher
S, Nitsch R and Wulczyn FG: Regulation of miRNA expression during
neural cell specification. Eur J Neurosci. 21:1469–1477. 2005.
View Article : Google Scholar : PubMed/NCBI
|
43
|
Krichevsky AM, King KS, Donahue CP,
Khrapko K and Kosik KS: A microRNA array reveals extensive
regulation of microRNAs during brain development. RNA. 9:1274–1281.
2003. View Article : Google Scholar : PubMed/NCBI
|
44
|
Wilting SM, van Boerdonk RA, Henken FE, et
al: Methylation-mediated silencing and tumour suppressive function
of hsa-miR-124 in cervical cancer. Mol Cancer. 9:1672010.
View Article : Google Scholar : PubMed/NCBI
|
45
|
Wang X, Tang S, Le SY, et al: Aberrant
expression of oncogenic and tumor-suppressive microRNAs in cervical
cancer is required for cancer cell growth. PloS one. 3:e25572008.
View Article : Google Scholar : PubMed/NCBI
|
46
|
Lee JW, Choi CH, Choi JJ, et al: Altered
MicroRNA expression in cervical carcinomas. Clin Cancer Res.
14:2535–2542. 2008. View Article : Google Scholar : PubMed/NCBI
|
47
|
van Solingen C, Seghers L, Bijkerk R, et
al: Antagomir-mediated silencing of endothelial cell specific
microRNA-126 impairs ischemia-induced angiogenesis. J Cell Mol Med.
13:1577–1585. 2009. View Article : Google Scholar : PubMed/NCBI
|
48
|
Wang S, Aurora AB, Johnson BA, et al: The
endothelial-specific microRNA miR-126 governs vascular integrity
and angiogenesis. Dev Cell. 15:261–271. 2008. View Article : Google Scholar : PubMed/NCBI
|
49
|
Meister J and Schmidt MH: miR-126 and
miR-126*: new players in cancer. Scientific World Journal.
10:2090–2100. 2010. View Article : Google Scholar
|
50
|
Sahasrabuddhe VV, Luhn P and Wentzensen N:
Human papillomavirus and cervical cancer: biomarkers for improved
prevention efforts. Future Microbiol. 6:1083–1098. 2011. View Article : Google Scholar : PubMed/NCBI
|
51
|
Liu L, Yu X, Guo X, et al: miR-143 is
downregulated in cervical cancer and promotes apoptosis and
inhibits tumor formation by targeting Bcl-2. Mol Med Rep.
5:753–760. 2012.
|
52
|
Wang F, Li Y, Zhou J, et al: miR-375 is
down-regulated in squamous cervical cancer and inhibits cell
migration and invasion via targeting transcription factor SP1. Am J
Pathol. 179:2580–2588. 2011. View Article : Google Scholar : PubMed/NCBI
|
53
|
Wei Q, Li YX, Liu M, Li X and Tang H:
MiR-17-5p targets TP53INP1 and regulates cell proliferation and
apoptosis of cervical cancer cells. IUBMB life. 64:697–704. 2012.
View Article : Google Scholar : PubMed/NCBI
|
54
|
Pang RT, Leung CO, Ye TM, et al:
MicroRNA-34a suppresses invasion through downregulation of Notch1
and Jagged1 in cervical carcinoma and choriocarcinoma cells.
Carcinogenesis. 31:1037–1044. 2010. View Article : Google Scholar : PubMed/NCBI
|
55
|
Trakooljul N, Hicks JA and Liu HC:
Identification of target genes and pathways associated with chicken
microRNA miR-143. Anim Genet. 41:357–364. 2010.PubMed/NCBI
|
56
|
Gao W, Yu Y, Cao H, Shen H, Li X, Pan S
and Shu Y: Deregulated expression of miR-21, miR-143 and miR-181a
in non small cell lung cancer is related to clinicopathologic
characteristics or patient prognosis. Biomed Pharmacother.
64:399–408. 2010. View Article : Google Scholar : PubMed/NCBI
|
57
|
Ahmad I, Singh LB, Yang ZH, et al: Mir143
expression inversely correlates with nuclear ERK5 immunoreactivity
in clinical prostate cancer. Br J Cancer. 108:149–154. 2013.
View Article : Google Scholar : PubMed/NCBI
|
58
|
Deftereos G, Corrie SR, Feng Q, et al:
Expression of mir-21 and mir-143 in cervical specimens ranging from
histologically normal through to invasive cervical cancer. PLoS
One. 6:e284232011. View Article : Google Scholar : PubMed/NCBI
|
59
|
Zhang H, Cai X, Wang Y, Tang H, Tong D and
Ji F: microRNA-143, down-regulated in osteosarcoma, promotes
apoptosis and suppresses tumorigenicity by targeting Bcl-2. Oncol
Rep. 24:1363–1369. 2010.PubMed/NCBI
|
60
|
Slaby O, Svoboda M, Fabian P, et al:
Altered expression of miR-21, miR-31, miR-143 and miR-145 is
related to clinicopathologic features of colorectal cancer.
Oncology. 72:397–402. 2007. View Article : Google Scholar
|
61
|
Kitade Y and Akao Y: MicroRNAs and their
therapeutic potential for human diseases: microRNAs, miR-143
and-145, function as anti-oncomirs and the application of
chemically modified miR-143 as an anti-cancer drug. J Pharmacol
Sci. 114:276–280. 2010. View Article : Google Scholar
|